Literature DB >> 10843901

Endothelial dysfunction does not require loss of endothelial nitric oxide synthase.

R R Giraldez1, A Panda, J L Zweier.   

Abstract

Whereas altered nitric oxide (NO.) formation from endothelial nitric oxide synthase (NOS) causes impaired vascular reactivity in a number of cardiovascular diseases, questions remain regarding how endothelial injury results in impaired NO. formation. It is unknown if loss of NOS expression or activity is required or if other factors are involved. Detergent treatment has been used to induce endothelial dysfunction. Therefore, NOS and NO. synthesis were characterized in a rat heart model of endothelial injury and dysfunction induced by the detergent Triton X-100. Cardiac NO. formation was directly measured by electron paramagnetic resonance spectroscopy. NOS activity was determined by the L-[(14)C]arginine conversion assay. Western blots and immunohistology were applied to define the amounts of NOS present in heart tissue before and after Triton treatment. Immunoelectron microscopy was performed to assess intracellular NOS distribution. A short bolus of Triton X-100, 0.25%, abolished responses to histamine and calcium ionophore while preserving response to nitroprusside. Complete blockade of NO. generation occurred after Triton treatment, but NOS activity assayed with addition of exogenous substrate and cofactors was unchanged, and identical 135-kDa NOS bands were seen on Western blots, indicating that NOS was not removed from the heart or structurally damaged by Triton. Immunohistochemistry showed no change in NOS localization after Triton treatment, and immunoelectron microscopy revealed similar NOS distribution in the plasma membrane and intracellular membranes. These results demonstrate that the endothelial dysfunction was due to decreased NO. synthesis but was not caused by loss or denaturation of NOS. Thus endothelial dysfunction due to mild endothelial membrane injury may occur in the presence of active NOS and is triggered by loss of NOS substrates or cofactors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843901     DOI: 10.1152/ajpheart.2000.278.6.H2020

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Depletion of NADP(H) due to CD38 activation triggers endothelial dysfunction in the postischemic heart.

Authors:  Levy A Reyes; James Boslett; Saradhadevi Varadharaj; Francesco De Pascali; Craig Hemann; Lawrence J Druhan; Giuseppe Ambrosio; Mohamed El-Mahdy; Jay L Zweier
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-21       Impact factor: 11.205

2.  Early ischaemic preconditioning requires Akt- and PKA-mediated activation of eNOS via serine1176 phosphorylation.

Authors:  Changjun Yang; M A Hassan Talukder; Saradhadevi Varadharaj; Murugesan Velayutham; Jay L Zweier
Journal:  Cardiovasc Res       Date:  2012-09-12       Impact factor: 10.787

3.  Inhibition of CD38 with the Thiazoloquin(az)olin(on)e 78c Protects the Heart against Postischemic Injury.

Authors:  James Boslett; Nikhil Reddy; Yasmin A Alzarie; Jay L Zweier
Journal:  J Pharmacol Exp Ther       Date:  2019-01-11       Impact factor: 4.030

4.  Luteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H).

Authors:  James Boslett; Craig Hemann; Yong Juan Zhao; Hon-Cheung Lee; Jay L Zweier
Journal:  J Pharmacol Exp Ther       Date:  2017-01-20       Impact factor: 4.030

Review 5.  Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.

Authors:  Derek W Edwardson; Rashmi Narendrula; Simon Chewchuk; Kyle Mispel-Beyer; Jonathan P J Mapletoft; Amadeo M Parissenti
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

6.  Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury.

Authors:  Guihao Chen; Chuansheng Xu; Thomas G Gillette; Tongyi Huang; Peisen Huang; Qing Li; Xiangdong Li; Qinfeng Li; Yu Ning; Ruijie Tang; Cunrong Huang; Yuyan Xiong; Xiaqiu Tian; Jun Xu; Junyan Xu; Liping Chang; Cong Wei; Chen Jin; Joseph A Hill; Yuejin Yang
Journal:  Theranostics       Date:  2020-09-23       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.